Alimera Sciences Stock Price. Everything You Need To Know About The Alimera Sciences Stock!
Alimera Sciences, Inc. is a biopharmaceutical company headquartered in Alpharetta, Georgia. With a workforce of 150 full-time employees, the company specializes in the research and development of prescription ophthalmic pharmaceuticals that focus on diseases affecting the retina. Since its IPO on April 22nd, 2010, the company has been engaged in the commercialization and development of innovative biopharmaceutical products.
Alimera Sciences, Inc.’s commercial product, ILUVIEN, is an intravitreal implant that delivers a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is used for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Additionally, ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
It is vital to research Alimera Sciences, Inc. and stay up-to-date with the latest news and developments in the biopharmaceutical industry. By keeping an eye on the stock price, shares, and market cap, you can gain valuable insight into the company’s performance and make informed investment decisions. Remember, investing always carries risk and investors should carefully consider their options before making any investment decisions. As a friendly reminder, this information is for educational purposes only and should not be considered financial advice.
Alimera Sciences Stock Price. Everything You Need To Know About The Alimera Sciences Stock! performance
- Employees 150
- Company HQ Alpharetta
- Website http://www.alimerasciences.com/
- ALIM Asset Type Common Stock
- ALIM Market Capitalization 190M
- Earnings Per Share -0.84
- Dividends Per Share None
- Dividend Date 2019-11-15
- Quarterly Earnings Growth 0
Investing in Alimera Sciences from Malaysia, Thailand, Indonesia, and Vietnam can be a strategic move to diversify your investment portfolio. As a leading global pharmaceutical company, Alimera Sciences focuses on eye care solutions, particularly in the treatment of retinal diseases. With their innovative products and cutting-edge technologies, Alimera Sciences is geared towards providing patients with a better quality of life. For retail investors from these countries, accessing Alimera stock through Zorion’s investment platform opens up opportunities to invest in real US stocks and Pre-IPO companies. By offering investment insights and recommendations, Zorion aims to empower investors to make informed decisions about their investments. Furthermore, Zorion provides educational resources and materials to expand investors’ knowledge and expertise in the field of investing. Start investing smartly in Alimera Sciences with Zorion today.
